IOL Chemicals Reports Record Quarterly Performance with Highest-Ever Revenue in Q1 FY27
IOL Chemicals and Pharmaceuticals Ltd., a leading Active Pharmaceutical Ingredient (API) manufacturer, has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported record quarterly performance, delivering its highest-ever revenue in the first quarter of Fiscal Year 2027 (Q1 FY27).The Q1 FY27 snapshot reflects substantial growth across key operational metrics, as detailed below:
| Particulars (₹ Cr) | Q1 FY27 | Q1 FY26 | Y-o-Y Growth |
|---|---|---|---|
| Revenue from Operations | 756.3 | 551.7 | 37.1% |
| EBITDA | 111.7 | 69.5 | 60.7% |
| PAT (Profit After Tax) | 64.5 | 34.0 | 89.9% |
| EBITDA Margin (%) | 14.6% | 12.4% | |
| PAT Margin (%) | 8.4% | 6.1% |
The company's performance in the previous quarters and fiscal year remains strong, with Q1 FY27 revenue rising 22.1% compared to Q4 FY26 (619.5 ₹ Cr), while EBITDA margin stood at 15.2% during the quarter. For the full Fiscal Year 2026 (FY26), Revenue from Operations reached 2,319.1 ₹ Cr and the company registered an EBITDA of 290.4 ₹ Cr.
Segment Highlights and Growth Drivers
Mr. Vikas Gupta, Joint Managing Director, commented on the results, noting that the record quarterly performance was particularly encouraging given prevailing geopolitical uncertainties, inflationary pressures, and supply chain disruptions in select raw materials.The growth across both business segments contributed significantly to the overall results:
- Pharmaceuticals Business: Revenue in the Pharmaceuticals segment saw a 43% year-on-year increase, while EBIT grew by 72% YoY. Non-Ibuprofen products accounted for 43% of Pharma revenue in Q1 FY27, up from 36% a year prior. This growth was driven by strong demand across Paracetamol, Pantoprazole, Metformin, Fenofibrate, and other APIs. Capacity utilisation for Paracetamol improved to 65%, up from 60% in the previous quarter.
- Chemicals Business: The Chemicals business delivered a 29% YoY revenue growth and experienced a substantial 193% YoY EBIT growth. This success was supported by better realisations, improved operational efficiencies, disciplined raw-material procurement, and increased exports.
International Expansion and Market Status
The company's export performance continues to strengthen, with exports contributing 28.5% of revenue in Q1 FY27, up from 24.4% in Q1 FY26, reflecting growing market traction internationally.A key operational achievement highlighted was the NMPA approval granted to IOL’s Clopidogrel API product in China, complementing its existing valid CEP registration and further expanding access to the Chinese pharmaceutical market.
Company Profile
IOL Chemicals and Pharmaceuticals Ltd., established in 1986 and based in Ludhiana, Punjab, is a leading Indian manufacturer of specialty chemicals and Active Pharmaceutical Ingredients (APIs). It stands as the world's largest producer of Ibuprofen with a 30% global market share. The company’s API portfolio covers critical therapeutic areas including anti-diabetics, cardiovascular care, pain management, and anti-convulsants. IOLCP exports to over 80 countries, including the USA, UK, China, and Germany.IOLCP Stock Price Movement
IOL Chemicals and Pharmaceuticals Limited shares today shed 2.29% in trading, concluding at ₹164.66 as the market closed post-session. The stock traded during the day between a low of ₹155 and a high of ₹178.79, with 15.14 million shares exchanged.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: